See also: Generic Pulmicort Flexhaler, Generic Pulmicort Turbuhaler
Pulmicort Respules is a brand name of budesonide, approved by the FDA in the following formulation(s):
PULMICORT RESPULES (budesonide - suspension; inhalation)
Manufacturer: ASTRAZENECA
Approval date: August 8, 2000
Strength(s): 0.25MG/2ML [AN], 0.5MG/2ML [AN], 1MG/2ML [RLD]
Has a generic version of Pulmicort Respules been approved?
A generic version of Pulmicort Respules has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Pulmicort Respules and have been approved by the FDA:
budesonide suspension; inhalation
Manufacturer: APOTEX
Approval date: March 30, 2009
Strength(s): 0.25MG/2ML [AN], 0.5MG/2ML [AN]
Manufacturer: TEVA PARENTERAL
Approval date: November 18, 2008
Strength(s): 0.25MG/2ML [AN], 0.5MG/2ML [AN]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pulmicort Respules. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method for treating respiratory diseases
Patent 6,598,603
Issued: July 29, 2003
Inventor(s): Bertil; Andersson & Thor-Björn; Conradsson & Göran; Eriksson
Assignee(s): Astra Aktiebolag
The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.Patent expiration dates:
- December 23, 2018✓
- June 23, 2019✓
- December 23, 2018
Method for treating a respiratory disease
Patent 6,899,099
Issued: May 31, 2005
Inventor(s): Andersson; Bertil & Conradsson; Thor-Björn & Eriksson; Göran
Assignee(s): AstraZeneca AB
The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.Patent expiration dates:
- December 23, 2018✓
- June 23, 2019✓
- December 23, 2018
Sterile powders, formulations, and methods for producing the same
Patent 7,524,834
Issued: April 28, 2009
Inventor(s): Karlsson; Ann-Kristin & Larrivee-Elkins; Cheryl & Molin; Ove
Assignee(s): AstraZeneca AB
The invention provides sterile glucocorticosteroids and sterile formulations containing glucocorticosteroid and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or the lungs.Patent expiration dates:
- November 11, 2018✓✓
- May 11, 2019✓
- November 11, 2018
See also...
- Pulmicort Respules Suspension Consumer Information (Wolters Kluwer)
- Pulmicort Respules Consumer Information (Cerner Multum)
- Pulmicort Respules Advanced Consumer Information (Micromedex)
- Budesonide Powder Consumer Information (Wolters Kluwer)
- Budesonide Suspension Consumer Information (Wolters Kluwer)
- Budesonide Sustained-Release Capsules Consumer Information (Wolters Kluwer)
- Budesonide Consumer Information (Cerner Multum)
- Budesonide inhalation Consumer Information (Cerner Multum)
- Pulmicort Spacer Advanced Consumer Information (Micromedex)
- Rhinocort Turbuhaler Advanced Consumer Information (Micromedex)
- Budesonide Advanced Consumer Information (Micromedex)
- Budesonide Inhalation Advanced Consumer Information (Micromedex)
- Budesonide AHFS DI Monographs (ASHP)
No comments:
Post a Comment